ClinicalTrials.gg
CompletedNCT02581410Updated Aug 28, 2018Results posted

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier

A Phase 3 interventional study of GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A) in Herpes Zoster, sponsored by GlaxoSmithKline. Completed at 32 sites in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-28.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
430
Allocation
Non-randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.

Enrollment
17th of 46
430 · median 239
Started
2015
the only one that year
Phase 3
22 of 46
2 open now
Registered
16th of 46
by date
Lead sponsor
26 of 46
GlaxoSmithKline

Among the 46 studies testing shingrix in Herpes Zoster, this one is the 17th largest by enrollment, is the only one that started in 2015, is one of 22 in phase 3, and was the 16th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About shingrix

shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing shingrix in Herpes Zoster, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in adults ≥ 65 years of age with and without Zostavax® vaccination at least 5 years earlier.

Read the detailed description

The study will evaluate two parallel groups of 200 adults ≥ 65 YOA; one group (Prev-Zvax) with a previous Zostavax® vaccination at least 5 years earlier, versus the other group without a previous Zostavax® vaccination (No prev-Zvax). The goal of this study is to generate immunogenicity, safety and reactogenicity data for the respective vaccines.

03

Conditions studied

  • Herpes Zoster

Browse trials for

Keywords

  • Zostavax®
  • ≥ 65 years of age
  • Herpes Zoster
  • Shingles
  • Immunogenicity
  • Safety
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • A male or female ≥ 65 years of age at the time of the first vaccination.
  • Written obtained from the subject prior to performing any study specific procedure.

For the No prev-Zvax group only:

  • No previous vaccination with Zostavax.

For the Prev-Zvax group only:

  • Previous vaccination with Zostavax ≥ 5 calendar years earlier.
  • Documentation indicating the date of previous Zostavax vaccination will be required.

Exclusion criteria

Exclusion Criteria:

  • Previous vaccination with Zostavax \< 5 calendar years earlier and/or anyone that ever received more than a single dose of Zostavax.
  • Previous vaccination against VZV, administration of HZ/su vaccine or any other or non-registered HZ vaccine (except Zostavax for the Prev-Zvax group).
  • Use of any investigational or non-registered product other than the study vaccine during the period starting 30 days before the first dose of study vaccine, or planned use during the study period.
  • Chronic administration (defined as > 14 consecutive days) of or other immune-modifying drugs in the period starting 6 months prior to the first dose of vaccine. (For , a prednisone dose of \< 20 mg/day, or equivalent, is allowed.) Inhaled, topical and intra-articular corticosteroids are allowed.
  • Administration of long-acting immune-modifying drugs (e.g., infliximab) in the period starting 6 months prior to the first vaccine dose or expected administration at any time during the study period.
  • Administration or planned administration of a in the period starting 30 days before the first dose of study vaccine and ending 30 days after the last dose of study vaccine, or, administration or planned administration of a non-replicating vaccine in the period starting 8 days prior to and ending 14 days after either dose of study vaccine.
  • Current participation in or planned concurrent participation in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
  • Planned administration of an HZ vaccine (including an investigational or non-registered vaccine) other than the study vaccine during the entire study.
  • History of HZ or any suspected HZ between the screening visit and Visit 1.
  • History of any reaction or likely to be exacerbated by any component of the vaccine/product.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease (e.g., , [HIV] infection) or immunosuppressive/cytotoxic therapy (e.g., medications used during cancer chemotherapy, organ transplantation or to treat disorders).
  • Acute disease and/or fever at the time of enrolment.

    • Fever is defined as temperature ≥ 37.5°C (99.5°F) by oral route, axillary or tympanic setting, or ≥ 38.0°C/100.4°F on rectal setting. The recommended route for recording temperature in this study will be oral.
    • Subjects with a minor illness (such as mild diarrhea, mild upper respiratory infection) without fever may be enrolled at the discretion of the investigator.
  • Administration of immunoglobulins and/or any blood products in the period starting 3 months preceding the first dose of study vaccine or planned administration during the study period.
  • Significant underlying illness that, in the opinion of the investigator, would be expected to prevent completion of the study.
  • Any other condition that, in the opinion of the investigator, might interfere with the evaluations required by the study.
  • Any condition which, in the judgment of the investigator, would make intramuscular (IM) injection unsafe.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
430 participants (actual)

Study arms

  • Experimental
    GSK1437173A Group

    Subjects ≥ 65 years of age who received Zostavax vaccine ≥ 5 years earlier and received 2 doses of the HZ/su vaccine (first dose given at Month 0 and second dose given 2 months later) in this study.

    Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)

  • Active comparator
    Control Group

    Subjects ≥ 65 years of age who never received Zostavax vaccine and received 2 doses of the HZ/su vaccine (first dose given at Month 0 and second dose given 2 months later) in this study.

    Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)

Interventions

  • BiologicalGSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)

    Drug page: Shingrix

    2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.

06

What researchers measure

Primary outcomes

  1. Anti-glycoprotein E (Anti-gE) Antibody (Ab) Concentrations

    Varicella Zoster Virus (VZV) gE Ab.Immunoglobulin G (IgG) was determined by Enzyme Linked Immunosorbent Assay (ELISA). Concentrations are presented as geometric mean concentrations (GMCs), expressed in milliinternational units per millilitre (mIU/mL). Geometric mean antibody concentrations were adjusted for group-matching variable.

    Time frame: One month after dose 2, at Month 3

  2. Number of Subjects With Solicited Local Symptoms

    Assessed solicited local symptoms were pain, redness and swelling. Any = Occurrence of the symptom regardless of its intensity grade. Grade 3 pain = Significant pain at rest that prevented normal everyday activities. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

    Time frame: During the 7-day (Days 0-6) period after each dose.

  3. Number of Days With Solicited Local Symptoms

    Solicited local symptoms were assessed during the 7-day (Days 0-6) period after each dose.

    Time frame: During the 7-day (Days 0-6) period after each dose.

  4. Number of Subjects With Solicited General Symptoms

    Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (included nausea, vomiting, diarrhea and/or abdominal pain), headache, myalgia, shivering and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\] . Any = Occurrence of the symptom regardless of its intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

    Time frame: During the 7-day (Days 0-6) period after each dose.

  5. Number of Days With Solicited General Symptoms

    Solicited general symptoms were assessed during the 7-day (Days 0-6) period after each dose.

    Time frame: During the 7-day (Days 0-6) period after each dose.

  6. Number of Subjects With Any, Grade 3 and Related Unsolicited Symptoms (AEs)

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

    Time frame: During the 30-day (Days 0-29) period after each dose.

  7. Number of Subjects With Any and Related Serious Adverse Events (SAEs)

    SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Related SAE = SAE assessed by the investigator as related to the vaccination.

    Time frame: From first vaccination (Month 0) up to 30 days post last vaccination (Month 3)

  8. Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs)

    pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

    Time frame: From first vaccination (Month 0) up to 30 days post last vaccination (Month 3)

Secondary outcomes

  1. Anti-gE Ab Concentrations

    VZV gE IgG antibody concentrations were determined by ELISA. Concentrations are presented as geometric mean concentrations (GMCs), expressed in milliinternational units per millilitre (mIU/mL).

    Time frame: At Months 0, 1, 3 and 14.

  2. Frequencies of gE-specific Cluster of Differentiation 4 (CD4+) T-cells

    gE-specific CD4+ T-cells, expressing at least two activation markers (from among interferon gamma \[IFN-γ\], interleukin-2 \[IL-2\], tumour necrosis factor alpha \[TNF-α\] and cluster of differentiation 40-ligand \[CD40L\]), as determined by in vitro Intracellular Cytokine Staining (ICS).

    Time frame: At Months 0, 1, 3 and 14.

  3. Number of Subjects With Any and Related SAEs

    SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Related SAE = SAE assessed by the investigator as related to the vaccination.

    Time frame: From 30 days post last vaccination (Month 3) until study end at Month 14

  4. Number of Subjects With Any pIMDs

    pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

    Time frame: From 30 days post last vaccination (Month 3) until study end at Month 14

07

Results

Posted Sep 26, 2017

Participant flow

Vaccination Phase
Participant flow — Vaccination Phase
MilestoneGSK1437173A GroupControl Group
Started215215
Completed213212
Not completed23
Withdrew: Adverse event21
Withdrew: Withdrawal by subject01
Withdrew: Migrated/moved from study area01
End of Study Phase
Participant flow — End of Study Phase
MilestoneGSK1437173A GroupControl Group
Started215215
Completed210204
Not completed511
Withdrew: Adverse event43
Withdrew: Withdrawal by subject12
Withdrew: Migrated/moved from study area03
Withdrew: Lost to follow-up02
Withdrew: Other-transfer of subject not completed01

Outcome measures

PrimaryAnti-glycoprotein E (Anti-gE) Antibody (Ab) Concentrations

Varicella Zoster Virus (VZV) gE Ab.Immunoglobulin G (IgG) was determined by Enzyme Linked Immunosorbent Assay (ELISA). Concentrations are presented as geometric mean concentrations (GMCs), expressed in milliinternational units per millilitre (mIU/mL). Geometric mean antibody concentrations were adjusted for group-matching variable.

Time frame:
One month after dose 2, at Month 3
Reported as:
Geometric mean · mIU/mL
Anti-glycoprotein E (Anti-gE) Antibody (Ab) Concentrations
mIU/mLGSK1437173A GroupControl Group
Anti-glycoprotein E (Anti-gE) Antibody (Ab) Concentrations50522.9 (44347.4 to 57558.4)48589.4 (42649.4 to 55356.6)
Statistical analysis
  • GSK1437173A Group vs Control Group · ANCOVA · Adjusted gmc ratio: 1.04 · 95% CI 0.92 to 1.17
PrimaryNumber of Subjects With Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = Occurrence of the symptom regardless of its intensity grade. Grade 3 pain = Significant pain at rest that prevented normal everyday activities. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

Time frame:
During the 7-day (Days 0-6) period after each dose.
Reported as:
Count of participants · Participants
Number of Subjects With Solicited Local Symptoms
ParticipantsGSK1437173A GroupControl Group
Any Pain, Dose 1171159
Grade 3 Pain, Dose 187
Any Redness, Dose 16948
Grade 3 Redness, Dose 132
Any Swelling, Dose 12921
Grade 3 Swelling, Dose 110
Any Pain, Dose 2163161
Grade 3 Pain, Dose 2510
Any Redness, Dose 26953
Grade 3 Redness, Dose 262
Any Swelling, Dose 22927
Grade 3 Swelling, Dose 201
PrimaryNumber of Days With Solicited Local Symptoms

Solicited local symptoms were assessed during the 7-day (Days 0-6) period after each dose.

Time frame:
During the 7-day (Days 0-6) period after each dose.
Reported as:
Median · Days
Number of Days With Solicited Local Symptoms
DaysGSK1437173A GroupControl Group
Any Pain, Dose 13.0 (2.0 to 4.0)2.0 (2.0 to 3.0)
Any Redness, Dose 13.0 (2.0 to 4.0)3.0 (2.0 to 4.0)
Any Swelling, Dose 12.0 (2.0 to 3.0)3.0 (2.0 to 4.0)
Any Pain, Dose 22.0 (2.0 to 3.0)2.0 (2.0 to 3.0)
Any Redness, Dose 23.0 (2.0 to 4.0)3.0 (2.0 to 5.0)
Any Swelling, Dose 22.0 (1.0 to 4.0)2.0 (1.0 to 4.0)
PrimaryNumber of Subjects With Solicited General Symptoms

Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (included nausea, vomiting, diarrhea and/or abdominal pain), headache, myalgia, shivering and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\] . Any = Occurrence of the symptom regardless of its intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

Time frame:
During the 7-day (Days 0-6) period after each dose.
Reported as:
Count of participants · Participants
Number of Subjects With Solicited General Symptoms
ParticipantsGSK1437173A GroupControl Group
Any Fatigue, Dose 16959
Grade 3 Fatigue, Dose 144
Related Fatigue, Dose 16248
Any Gastro. int., Dose 13114
Grade 3 Gastro. int., Dose 122
Related Gastro. int., Dose 1249
Any Headache, Dose 14144
Grade 3 Headache, Dose 141
Related Headache, Dose 13434
Any Myalgia, Dose 14742
Grade 3 Myalgia, Dose 125
Related Myalgia, Dose 14137
Any Shivering, Dose 12517
Grade 3 Shivering, Dose 121
Related Shivering, Dose 12216
Any Fever, Dose 11517
Grade 3 Fever, Dose 100
Related Fever, Dose 11214
Any Fatigue, Dose 29193
Grade 3 Fatigue, Dose 2911
Related Fatigue, Dose 28584
Any Gastro. int., Dose 23027
Grade 3 Gastro. int., Dose 200
Related Gastro. int., Dose 23022
Any Headache, Dose 26266
Grade 3 Headache, Dose 223
Related Headache, Dose 25758
Any Myalgia, Dose 26153
Grade 3 Myalgia, Dose 265
Related Myalgia, Dose 25651
Any Shivering, Dose 23626
Grade 3 Shivering, Dose 243
Related Shivering, Dose 23424
Any Fever, Dose 22619
Grade 3 Fever, Dose 200
Related Fever, Dose 22418
PrimaryNumber of Days With Solicited General Symptoms

Solicited general symptoms were assessed during the 7-day (Days 0-6) period after each dose.

Time frame:
During the 7-day (Days 0-6) period after each dose.
Reported as:
Median · Days
Number of Days With Solicited General Symptoms
DaysGSK1437173A GroupControl Group
Any Fatigue, Dose 11.0 (1.0 to 3.0)1.0 (1.0 to 3.0)
Any Gastrointestinal symptoms, Dose 11.0 (1.0 to 2.0)1.0 (1.0 to 2.0)
Any Headache, Dose 11.0 (1.0 to 2.0)1.0 (1.0 to 2.0)
Any Myalgia, Dose 12.0 (1.0 to 3.0)2.0 (1.0 to 3.0)
Any Shivering, Dose 11.0 (1.0 to 1.0)1.0 (1.0 to 2.0)
Any Temperature, Dose 11.0 (1.0 to 1.0)1.0 (1.0 to 1.0)
Any Fatigue, Dose 21.0 (1.0 to 2.0)2.0 (1.0 to 3.0)
Any Gastrointestinal symptoms, Dose 21.0 (1.0 to 1.0)1.0 (1.0 to 2.0)
Any Headache, Dose 21.0 (1.0 to 2.0)1.0 (1.0 to 2.0)
Any Myalgia, Dose 21.0 (1.0 to 2.0)1.0 (1.0 to 2.0)
Any Shivering, Dose 21.0 (1.0 to 1.0)1.0 (1.0 to 1.0)
Any Temperature, Dose 21.0 (1.0 to 1.0)1.0 (1.0 to 1.0)
PrimaryNumber of Subjects With Any, Grade 3 and Related Unsolicited Symptoms (AEs)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

Time frame:
During the 30-day (Days 0-29) period after each dose.
Reported as:
Count of participants · Participants
Number of Subjects With Any, Grade 3 and Related Unsolicited Symptoms (AEs)
ParticipantsGSK1437173A GroupControl Group
Any AEs8154
Grade 3 AEs145
Related AEs1313
PrimaryNumber of Subjects With Any and Related Serious Adverse Events (SAEs)

SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Related SAE = SAE assessed by the investigator as related to the vaccination.

Time frame:
From first vaccination (Month 0) up to 30 days post last vaccination (Month 3)
Reported as:
Count of participants · Participants
Number of Subjects With Any and Related Serious Adverse Events (SAEs)
ParticipantsGSK1437173A GroupControl Group
Any SAEs44
Related SAEs00
PrimaryNumber of Subjects With Any Potential Immune-mediated Diseases (pIMDs)

pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

Time frame:
From first vaccination (Month 0) up to 30 days post last vaccination (Month 3)
Reported as:
Count of participants · Participants
Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs)
ParticipantsGSK1437173A GroupControl Group
Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs)21
SecondaryAnti-gE Ab Concentrations

VZV gE IgG antibody concentrations were determined by ELISA. Concentrations are presented as geometric mean concentrations (GMCs), expressed in milliinternational units per millilitre (mIU/mL).

Time frame:
At Months 0, 1, 3 and 14.
Reported as:
Geometric mean · mIU/mL
Anti-gE Ab Concentrations
mIU/mLGSK1437173A GroupControl Group
At Month 01784.3 (1572.9 to 2024.1)1408.5 (1203.3 to 1648.8)
At Month 129959.0 (26633.6 to 33699.6)25233.7 (22072.3 to 28848.0)
At Month 349327.2 (45388.2 to 53608.1)51618.5 (47224.8 to 56420.9)
At Month 1417783.6 (16077.1 to 19671.4)15784.1 (14180.2 to 17569.4)
SecondaryFrequencies of gE-specific Cluster of Differentiation 4 (CD4+) T-cells

gE-specific CD4+ T-cells, expressing at least two activation markers (from among interferon gamma \[IFN-γ\], interleukin-2 \[IL-2\], tumour necrosis factor alpha \[TNF-α\] and cluster of differentiation 40-ligand \[CD40L\]), as determined by in vitro Intracellular Cytokine Staining (ICS).

Time frame:
At Months 0, 1, 3 and 14.
Reported as:
Mean · CD4+ T-cells/million T-cells
Frequencies of gE-specific Cluster of Differentiation 4 (CD4+) T-cells
CD4+ T-cells/million T-cellsGSK1437173A GroupControl Group
At Month 089.09 ± 99.7390.88 ± 97.5
At Month 1562.17 ± 532.58534.57 ± 523.97
At Month 32946.02 ± 2088.482843.89 ± 2111.54
At Month 141290.98 ± 1181.891126.44 ± 1012.28
SecondaryNumber of Subjects With Any and Related SAEs

SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Related SAE = SAE assessed by the investigator as related to the vaccination.

Time frame:
From 30 days post last vaccination (Month 3) until study end at Month 14
Reported as:
Count of participants · Participants
Number of Subjects With Any and Related SAEs
ParticipantsGSK1437173A GroupControl Group
Any SAEs1518
Related SAEs00
SecondaryNumber of Subjects With Any pIMDs

pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

Time frame:
From 30 days post last vaccination (Month 3) until study end at Month 14
Reported as:
Count of participants · Participants
Number of Subjects With Any pIMDs
ParticipantsGSK1437173A GroupControl Group
Number of Subjects With Any pIMDs13

Adverse events

Collected over Solicited local and general AEs were assessed during a 7-day follow-up period (Days 0-6) after each vaccination visit. Unsolicited AEs were assessed for a period of 30 days (Days 0-29) after each vaccination visit. SAEs were assessed from the first receipt of the study vaccine (Month 0) up to study end (Month 14).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK1437173A Group2/215 (0.9%)18/215 (8.4%)199/215 (92.6%)
Control Group3/215 (1.4%)22/215 (10.2%)197/215 (91.6%)
Most frequent serious events
Showing 10 of 59
Most frequent serious events
EventGSK1437173A GroupControl Group
Atrial fibrillationCardiac disorders2/2150/215
Coronary artery diseaseCardiac disorders0/2152/215
CellulitisInfections and infestations2/2151/215
DehydrationMetabolism and nutrition disorders1/2152/215
LeukocytosisBlood and lymphatic system disorders0/2151/215
ArrhythmiaCardiac disorders0/2151/215
Atrioventricular blockCardiac disorders0/2151/215
Cardiac arrestCardiac disorders0/2151/215
Myocardial infarctionCardiac disorders0/2151/215
PalpitationsCardiac disorders1/2150/215
Most frequent other events
Most frequent other events
EventGSK1437173A GroupControl Group
PainGeneral disorders189/215181/215
FatigueGeneral disorders114/215111/215
ErythemaSkin and subcutaneous tissue disorders96/21573/215
HeadacheNervous system disorders80/21589/215
MyalgiaMusculoskeletal and connective tissue disorders82/21578/215
ChillsGeneral disorders51/21537/215
SwellingGeneral disorders50/21537/215
Gastrointestinal disorderGastrointestinal disorders49/21538/215
PyrexiaGeneral disorders36/21532/215

Baseline characteristics

Age, Continuous
Age, Continuous(Years)GSK1437173A GroupControl GroupTotal
Mean71.1 ± 4.570.8 ± 4.670.9 ± 4.6
Sex: Female, Male
Sex: Female, Male(Participants)GSK1437173A GroupControl GroupTotal
Female109111220
Male106104210
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GSK1437173A GroupControl GroupTotal
White - Caucasian / European Heritage — White - Caucasian / European Heritage215215430
08

Study locations

32 sites
  • GSK Investigational Site
    Huntsville, Alabama 35802, United States
  • GSK Investigational Site
    Daly City, California 94015, United States
  • GSK Investigational Site
    Los Gatos, California 95032, United States
  • GSK Investigational Site
    Oakland, California 94612, United States
  • GSK Investigational Site
    Roseville, California 95661, United States
  • GSK Investigational Site
    Santa Rosa, California 95405, United States
  • GSK Investigational Site
    Boise, Idaho 83642, United States
  • GSK Investigational Site
    Lenexa, Kansas 66219, United States
  • GSK Investigational Site
    Newton, Kansas 67114, United States
  • GSK Investigational Site
    Wichita, Kansas 67207, United States
  • GSK Investigational Site
    Auburn, Maine 04210, United States
  • GSK Investigational Site
    Columbia, Maryland 21045, United States
  • GSK Investigational Site
    Elkridge, Maryland 21075, United States
  • GSK Investigational Site
    Marlborough, Massachusetts 01752, United States
  • GSK Investigational Site
    Binghamton, New York 13901, United States
  • GSK Investigational Site
    Endwell, New York 13760, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28209, United States
  • GSK Investigational Site
    Cleveland, Ohio 44122, United States
  • GSK Investigational Site
    Corvallis, Oregon 97330, United States
  • GSK Investigational Site
    Erie, Pennsylvania 16506, United States
  • GSK Investigational Site
    Erie, Pennsylvania 16508, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • GSK Investigational Site
    Uniontown, Pennsylvania 15401, United States
  • GSK Investigational Site
    Mount Pleasant, South Carolina 29464, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303, United States
  • GSK Investigational Site
    Layton, Utah 84041, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84109, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84121, United States
  • GSK Investigational Site
    South Jordan, Utah 84095, United States
  • GSK Investigational Site
    Newport News, Virginia 23606, United States
  • GSK Investigational Site
    Eau Claire, Wisconsin 54701, United States
  • GSK Investigational Site
    Marshfield, Wisconsin 54449, United States
09

References and documents

Publications

  • Dagnew AF, Klein NP, Herve C, Kalema G, Di Paolo E, Peterson J, Salaun B, Schuind A. The Adjuvanted Recombinant Zoster Vaccine in Adults Aged >/=65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine. J Infect Dis. 2021 Oct 13;224(7):1139-1146. doi: 10.1093/infdis/jiaa083. PubMed 32103273 ↗
  • Grupping K, Campora L, Douha M, Heineman TC, Klein NP, Lal H, Peterson J, Vastiau I, Oostvogels L. Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine. J Infect Dis. 2017 Dec 12;216(11):1343-1351. doi: 10.1093/infdis/jix482. PubMed 29029122 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Aug 2016, 8 months.

Results were first posted in Sep 2017, 1 year after primary completion.

Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 8 months is below that.

Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2015
First posted
Oct 21, 2015
StartActual
Dec 15, 2015
Primary completionActual
Aug 30, 2016
CompletionActual
Aug 1, 2017
Results first posted
Sep 26, 2017
Last update
Aug 28, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02581410
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 21, 2015
Start date
Dec 15, 2015
Primary completion
Aug 30, 2016
Completion
Aug 1, 2017
Results posted
Sep 26, 2017
Last update
Aug 28, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Shingrix

Start the discussion